Compare Amgen, Inc. (AMGN) vs Under Armour Inc Class A (UA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Under Armour Inc Class A — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Under Armour Inc Class A trades at $6.54 (market cap $2.86B). The key difference: Amgen, Inc. is far larger — about 68.6× Under Armour Inc Class A's market cap, and Amgen, Inc. pays a 2.77% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.
| AMGN | UA | |
|---|---|---|
Market Cap | $196.12B | $2.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $7.88 |
52-Week Low | $271.18 | $3.96 |
Enterprise Value | $241.41B | $4.49B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Under Armour (UA) trades at $6.61, up 2.48% with a bullish technical signal from moving averages. The company reported mixed Q1 2026 results with an EPS miss but maintains a 40.3% analyst buy rating. Recent financials show revenue of $5.16B for 2025 with negative net income of -$201.27M, though gross margins remain healthy at 45.48%. The Dodge collaboration and institutional buying by Prem Watsa provide positive catalysts amid ongoing business restructuring.
The outlook remains challenging with declining revenue projections and negative profitability metrics, but current valuation at 0.57 P/S offers potential for turnaround investors. Key risks include sustained revenue declines, competitive pressures, and negative cash flow trends. Institutional sentiment appears cautiously optimistic despite fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
